Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

US7485633B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Nicholas A. Meanwell · East Hampton, US
• Robert G. Gentles · Killingworth, US
• Min Ding · Dobbs Ferry, US
• John A. Bender · Middletown, US
• John F. Kadow · Wallingford, US
• Piyasena Hewawasam · Middletown, US
• Thomas W. Hudyma · Durham, US
• Xiaofan Zheng · Cheshire, US

Key dates

• Filing date: Mar 12, 2007
• Grant date: Feb 3, 2009
• Expiry date: Mar 12, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.